Midatech Pharma PLC Receipt of NASDAQ Notification (3015X)
27 April 2019 - 1:30AM
UK Regulatory
TIDMMTPH
RNS Number : 3015X
Midatech Pharma PLC
26 April 2019
26 April 2019
Midatech Pharma PLC
("Midatech", the "Company" or the "Group")
Receipt of NASDAQ Notification
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the R&D company
focused on delivering innovative oncology and rare disease products
to patients, announces that further to the Company's announcement
on 3 May 2018, it received written notification on 23 April 2019
(the "Notification Letter") from The NASDAQ Stock Market LLC
("NASDAQ") that for the last 10 consecutive business days, from
April 8 to April 22 2019, the closing bid price of the Company's
American Depositary Shares had been at $1.00 per share or greater
and, accordingly, the Company has regained compliance with NASDAQ
Listing Rule 5550(a)(2).
- Ends -
For more information, please contact:
Midatech Pharma PLC
Dr Craig Cook, CEO
Tel: +44 (0)1235 888300
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Corporate Finance
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Tel: +44 (0)20 7886 2500
IFC Advisory Limited (Financial PR and UK Investor
Relations)
Graham Herring / Tim Metcalfe / Heather Armstrong
Tel: +44 (0)20 3709 5700
Email: midatech@investor-focus.co.uk
Westwicke Partners (US Investor Relations)
Chris Brinzey
Tel: +1 339 970 2843
Email: chris.brinzey@westwicke.com
Notes for Editors
About Midatech Pharma PLC
Midatech Pharma (LSE AIM: MTPH; NASDAQ: MTP) is an R&D
company focused on delivering innovative oncology and rare disease
products to patients. The Company is developing a range of improved
chemo-therapeutics or new immuno-therapeutics, using its
three-proprietary platform drug delivery technologies, all of which
are in the clinic, specifically:
1. Q-Sphera(TM) platform: our disruptive polymer microsphere
technology used for sustained release at the microscale to prolong
and control the release of therapeutics over an extended period of
time from weeks to months.
2. MidaCore(TM) platform: our leading-edge gold nanoparticle
technology used for targeting sites of disease at the nanoscale
i.e. chemotherapy - improved and targeted delivery of existing
chemotherapeutic agents to tumour sites, as well as ii.
immunotherapy - enhanced uptake of new immuno-moieties by immune
cells that can then mount an immune attack against cancer
cells.
3. MidaSolve platform: our innovative nanosaccharide technology
used to dissolve otherwise insoluble drugs at the nanoscale so that
they can be administered in liquid form directly and locally into
tumours.
Each of our three technologies are thus focussed on improved
bio-delivery and bio-distribution of medicines or agents to areas
of the body where they are needed and can exert their actions in an
effective, safe and precise manner.
Midatech's headquarters and R&D facility is in Cardiff, UK,
with a manufacturing operation in Bilbao, Spain. For more
information please visit www.midatechpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEASLKAASNEFF
(END) Dow Jones Newswires
April 26, 2019 11:30 ET (15:30 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From May 2023 to May 2024